Full Text Journal Articles by
Author David DeMets

Advertisement

Find full text journal articles






Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.

Kieran F Docherty, Pardeep S Jhund, Brian Claggett, João Pedro Ferreira, Olof Bengtsson, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, John J V McMurray, ,

<h4>Importance</h4>Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to clinical trial results when communicating the benefits of this class of drug ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Genomic surveillance to combat COVID-19: challenges and opportunities.

Janet D Robishaw, Scott M Alter, Joshua J Solano, Richard D Shih, David L DeMets, Dennis G Maki, Charles H Hennekens,

Although the development and increasingly widespread availability of effective and safe vaccines provides the greatest hope for the future recovery from the increasingly devastating COVID-19 pandemic, there are other preventive efforts that offer an immediate route to decreasing morbidity and mortality. Genomic surveillance is emerging as a vital necessity to ... Read more >>

Lancet Microbe (The Lancet. Microbe)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

COVID-19 control in the United States: the case for masking.

Dennis G Maki, Scott M Alter, Joshua J Solano, Terry A Adirim, David L DeMets, Richard D Shih, Charles H Hennekens,

As of May 2021, the United States remains the world leader with 33 million of 165 million cases worldwide (20%) and 590,000 of 3.4 million deaths worldwide (17%) from COVID-19. Achieving herd immunity by disease spread and vaccination may result in 2 million to 4 million total US deaths. The ... Read more >>

Am J Manag Care (The American journal of managed care)
[2021, 27(7):e218-e220]

Cited: 0 times

View full text PDF listing >>



Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.

Scott D Solomon, Rudolf A de Boer, David DeMets, Adrian F Hernandez, Silvio E Inzucchi, Mikhail N Kosiborod, Carolyn S P Lam, Felipe Martinez, Sanjiv J Shah, Daniel Lindholm, Ulrica Wilderäng, Fredrik Öhrn, Brian Claggett, Anna Maria Langkilde, Magnus Petersson, John J V McMurray,

<h4>Aims</h4>Sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally developed as glucose-lowering agents, have been shown to reduce heart failure hospitalizations in patients with type 2 diabetes without established heart failure, and in patients with heart failure with and without diabetes. Their role in patients with heart failure with preserved and mildly reduced ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2021, 23(7):1217-1225]

Cited: 0 times

View full text PDF listing >>



Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.

,

<h4>Background</h4>Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.<h4>Methods</h4>This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised ... Read more >>

Lancet (Lancet (London, England))
[2021, 397(10289):2049-2059]

Cited: 8 times

View full text PDF listing >>



Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

,

<h4>Background</h4>In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.<h4>Methods</h4>This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those ... Read more >>

Lancet (Lancet (London, England))
[2021, 397(10285):1637-1645]

Cited: 60 times

View full text PDF listing >>



The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy.

Bethany Doran, Chaoqun Mei, Paul D Varosy, David P Kao, Leslie A Saxon, Arthur M Feldman, David DeMets, Michael R Bristow,

<h4>Objectives</h4>The aim of this study was to determine whether patients with heart failure with reduced ejection fraction (HFrEF) due to nonischemic etiology eligible for cardiac resynchronization therapy (CRT) benefit from an implantable cardioverter-defibrillator (ICD).<h4>Background</h4>It is uncertain whether CRT with an ICD (CRT-D) compared to without an ICD (CRT-P) is associated ... Read more >>

JACC Heart Fail (JACC. Heart failure)
[2021, 9(6):439-449]

Cited: 0 times

View full text PDF listing >>



Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

,

<h4>Background</h4>Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.<h4>Methods</h4>In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were ... Read more >>

Lancet (Lancet (London, England))
[2021, 397(10274):605-612]

Cited: 24 times

View full text PDF listing >>



Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.

Orly Vardeny, KyungMann Kim, Jacob A Udell, Jacob Joseph, Akshay S Desai, Michael E Farkouh, Sheila M Hegde, Adrian F Hernandez, Allison McGeer, H Keipp Talbot, Inder Anand, Deepak L Bhatt, Christopher P Cannon, David DeMets, J Michael Gaziano, Shaun G Goodman, Kristin Nichol, Matthew C Tattersall, Jonathan L Temte, Janet Wittes, Clyde Yancy, Brian Claggett, Yi Chen, Lu Mao, Thomas C Havighurst, Lawton S Cooper, Scott D Solomon, ,

<h4>Importance</h4>Influenza is temporally associated with cardiopulmonary morbidity and mortality among those with cardiovascular disease who may mount a less vigorous immune response to vaccination. Higher influenza vaccine dose has been associated with reduced risk of influenza illness.<h4>Objective</h4>To evaluate whether high-dose trivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine would ... Read more >>

JAMA (JAMA)
[2021, 325(1):39-49]

Cited: 2 times

View full text PDF listing >>



Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.

Kieran F Docherty, Pardeep S Jhund, Inder Anand, Olof Bengtsson, Michael Böhm, Rudolf A de Boer, David L DeMets, Akshay S Desai, Jaroslaw Drozdz, Jonathan Howlett, Silvio E Inzucchi, Per Johanson, Tzvetana Katova, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Daniel Lindholm, Felipe A Martinez, Béla Merkely, Jose C Nicolau, Eileen O'Meara, Piotr Ponikowski, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, Sergey Tereshchenko, Subodh Verma, John J V McMurray,

<h4>Background</h4>In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk of mortality and heart failure (HF) hospitalization. We examined the frequency and significance of episodes of outpatient HF worsening, requiring the augmentation of oral therapy, and the effects of ... Read more >>

Circulation (Circulation)
[2020, 142(17):1623-1632]

Cited: 4 times

View full text PDF listing >>



Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).

Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Scott D Solomon, David L DeMets, Olof Bengtsson, Mikaela Sjöstrand, Anna Maria Langkilde, Inder S Anand, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer, Mirta Diez, Andrej Dukát, Junbo Ge, Jonathan G Howlett, Tzvetana Katova, Masafumi Kitakaze, Charlotta E A Ljungman, Subodh Verma, Kieran F Docherty, Pardeep S Jhund, John J V McMurray,

<h4>Aims</h4>Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of dapagliflozin, which lowers systolic blood pressure (SBP),according to baseline SBP in Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).<h4>Methods and ... Read more >>

Eur Heart J (European heart journal)
[2020, 41(36):3402-3418]

Cited: 6 times

View full text PDF listing >>



Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.

Kieran F Docherty, Pardeep S Jhund, Olof Bengtsson, David L DeMets, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, John J V McMurray, ,

<h4>Objective</h4>To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).<h4>Research design and methods</h4>We examined the effect of study treatment by the ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(11):2878-2881]

Cited: 1 time

View full text PDF listing >>



Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.

Alice M Jackson, Pooja Dewan, Inder S Anand, Jan Bělohlávek, Olof Bengtsson, Rudolf A de Boer, Michael Böhm, David W Boulton, Vijay K Chopra, David L DeMets, Kieran F Docherty, Andrej Dukát, Peter J Greasley, Jonathan G Howlett, Silvio E Inzucchi, Tzvetana Katova, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Daniel Lindholm, Charlotta E A Ljungman, Felipe A Martinez, Eileen O'Meara, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, Sergey Tereshchenko, Subodh Verma, Pardeep S Jhund, John J V McMurray,

<h4>Background</h4>In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of worsening heart failure and death in patients with heart failure and reduced ejection fraction. We examined the efficacy and tolerability of dapagliflozin in relation to background diuretic treatment ... Read more >>

Circulation (Circulation)
[2020, 142(11):1040-1054]

Cited: 8 times

View full text PDF listing >>



Achieving effective informed oversight by DMCs in COVID clinical trials.

David L DeMets, Thomas R Fleming,

Best practices of data monitoring committees (DMCs) in randomized clinical trials are well established. Independent oversight provided by DMCs is particularly important in trials conducted in public health emergencies, such as in HIV/AIDS or coronavirus epidemics. Special considerations are needed to enable DMCs to effectively address novel circumstances they face ... Read more >>

J Clin Epidemiol (Journal of clinical epidemiology)
[2020, 126:167-171]

Cited: 3 times

View full text PDF listing >>



Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.

Kieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, David L DeMets, Marc S Sabatine, Olof Bengtsson, Mikaela Sjöstrand, Anna Maria Langkilde, Akshay S Desai, Mirta Diez, Jonathan G Howlett, Tzvetana Katova, Charlotta E A Ljungman, Eileen O'Meara, Mark C Petrie, Morten Schou, Subodh Verma, Pham Nguyen Vinh, Scott D Solomon, John J V McMurray,

<h4>Aims</h4>In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy.<h4>Methods and results</h4>In this post hoc analysis, we examined the effect of ... Read more >>

Eur Heart J (European heart journal)
[2020, 41(25):2379-2392]

Cited: 11 times

View full text PDF listing >>



Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.

Pooja Dewan, Scott D Solomon, Pardeep S Jhund, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, David L DeMets, Marc S Sabatine, Olof Bengtsson, Mikaela Sjöstrand, Anna Maria Langkilde, Inder S Anand, Jan Bělohlávek, Vijay K Chopra, Andrej Dukát, Masafumi Kitakaze, Béla Merkely, Eileen O'Meara, Morten Schou, Pham Nguyen Vinh, John J V McMurray, ,

<h4>Aims</h4>The aim of this study was to examine whether left ventricular ejection fraction (LVEF) modified efficacy and safety of dapagliflozin 10 mg compared with placebo in the 4744 patients with LVEF ≤40% randomized in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF).<h4>Methods and results</h4>We examined whether LVEF, analysed categorically ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2020, 22(7):1247-1258]

Cited: 2 times

View full text PDF listing >>



Mindfulness with paced breathing reduces blood pressure.

Jacqueline Brenner, Suzanne LeBlang, Michelle Lizotte-Waniewski, Barbara Schmidt, Patricio S Espinosa, David L DeMets, Andrew Newberg, Charles H Hennekens,

Elevated blood pressure (BP) is a major avoidable cause of premature morbidity and mortality in the United States (US) and worldwide, due primarily to increased risks of stroke as well as myocardial infarction. While there are therapeutic lifestyle changes and adjunctive pharmacologic medications of proven benefit, recent interest has increasingly ... Read more >>

Med Hypotheses (Medical hypotheses)
[2020, 142:109780]

Cited: 0 times

View full text PDF listing >>



Initial Invasive or Conservative Strategy for Stable Coronary Disease.

David J Maron, Judith S Hochman, Harmony R Reynolds, Sripal Bangalore, Sean M O'Brien, William E Boden, Bernard R Chaitman, Roxy Senior, Jose López-Sendón, Karen P Alexander, Renato D Lopes, Leslee J Shaw, Jeffrey S Berger, Jonathan D Newman, Mandeep S Sidhu, Shaun G Goodman, Witold Ruzyllo, Gilbert Gosselin, Aldo P Maggioni, Harvey D White, Balram Bhargava, James K Min, G B John Mancini, Daniel S Berman, Michael H Picard, Raymond Y Kwong, Ziad A Ali, Daniel B Mark, John A Spertus, Mangalath N Krishnan, Ahmed Elghamaz, Nagaraja Moorthy, Whady A Hueb, Marcin Demkow, Kreton Mavromatis, Olga Bockeria, Jesus Peteiro, Todd D Miller, Hanna Szwed, Rolf Doerr, Matyas Keltai, Joseph B Selvanayagam, P Gabriel Steg, Claes Held, Shun Kohsaka, Stavroula Mavromichalis, Ruth Kirby, Neal O Jeffries, Frank E Harrell, Frank W Rockhold, Samuel Broderick, T Bruce Ferguson, David O Williams, Robert A Harrington, Gregg W Stone, Yves Rosenberg, ,

<h4>Background</h4>Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain.<h4>Methods</h4>We randomly assigned 5179 patients with moderate or severe ischemia to an initial invasive strategy ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 382(15):1395-1407]

Cited: 136 times

View full text PDF listing >>



Management of Coronary Disease in Patients with Advanced Kidney Disease.

Sripal Bangalore, David J Maron, Sean M O'Brien, Jerome L Fleg, Evgeny I Kretov, Carlo Briguori, Upendra Kaul, Harmony R Reynolds, Tomasz Mazurek, Mandeep S Sidhu, Jeffrey S Berger, Roy O Mathew, Olga Bockeria, Samuel Broderick, Radoslaw Pracon, Charles A Herzog, Zhen Huang, Gregg W Stone, William E Boden, Jonathan D Newman, Ziad A Ali, Daniel B Mark, John A Spertus, Karen P Alexander, Bernard R Chaitman, Glenn M Chertow, Judith S Hochman, ,

<h4>Background</h4>Clinical trials that have assessed the effect of revascularization in patients with stable coronary disease have routinely excluded those with advanced chronic kidney disease.<h4>Methods</h4>We randomly assigned 777 patients with advanced kidney disease and moderate or severe ischemia on stress testing to be treated with an initial invasive strategy consisting of ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 382(17):1608-1618]

Cited: 36 times

View full text PDF listing >>



Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease.

John A Spertus, Philip G Jones, David J Maron, Sean M O'Brien, Harmony R Reynolds, Yves Rosenberg, Gregg W Stone, Frank E Harrell, William E Boden, William S Weintraub, Khaula Baloch, Kreton Mavromatis, Ariel Diaz, Gilbert Gosselin, Jonathan D Newman, Stavroula Mavromichalis, Karen P Alexander, David J Cohen, Sripal Bangalore, Judith S Hochman, Daniel B Mark, ,

<h4>Background</h4>In the ISCHEMIA trial, an invasive strategy with angiographic assessment and revascularization did not reduce clinical events among patients with stable ischemic heart disease and moderate or severe ischemia. A secondary objective of the trial was to assess angina-related health status among these patients.<h4>Methods</h4>We assessed angina-related symptoms, function, and quality ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 382(15):1408-1419]

Cited: 29 times

View full text PDF listing >>



Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease.

John A Spertus, Philip G Jones, David J Maron, Daniel B Mark, Sean M O'Brien, Jerome L Fleg, Harmony R Reynolds, Gregg W Stone, Mandeep S Sidhu, Bernard R Chaitman, Glenn M Chertow, Judith S Hochman, Sripal Bangalore, ,

<h4>Background</h4>In the ISCHEMIA-CKD trial, the primary analysis showed no significant difference in the risk of death or myocardial infarction with initial angiography and revascularization plus guideline-based medical therapy (invasive strategy) as compared with guideline-based medical therapy alone (conservative strategy) in participants with stable ischemic heart disease, moderate or severe ischemia, ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 382(17):1619-1628]

Cited: 5 times

View full text PDF listing >>



Correlation Between Oral Health and Systemic Inflammation (COHESION): A Randomized Pilot Follow-Up Trial of a Plaque-Identifying Toothpaste.

Amit Acharya, Ingrid Glurich, Scott Hetzel, KyungMann Kim, Matthew C Tattersall, David L DeMets, Charles H Hennekens,

<h4>Background</h4>Inflammation is intimately involved in the pathogenesis of atherosclerosis and is accurately measured by high-sensitivity C-reactive protein (hs-CRP), a sensitive marker for future risk of cardiovascular disease. The Correlation between Oral Health and Systemic Inflammation (COHESION) trial was designed to test the hypothesis that PlaqueHD, a plaque-identifying toothpaste, reduces hs-CRP.<h4>Methods</h4>The ... Read more >>

Am J Med (The American journal of medicine)
[2020, 133(8):994-998]

Cited: 0 times

View full text PDF listing >>



Aspirin in Primary Prevention: Needs Individual Clinical Judgments.

Alexander Gitin, Marc A Pfeffer, David L DeMets, Charles H Hennekens,

Am J Med (The American journal of medicine)
[2020, 133(7):774-776]

Cited: 0 times

View full text PDF listing >>



When Can Intermediate Outcomes Be Used as Surrogate Outcomes?

David L DeMets, Bruce M Psaty, Thomas R Fleming,

JAMA (JAMA)
[2020, 323(12):1184-1185]

Cited: 3 times

View full text PDF listing >>



Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.

Felipe A Martinez, Matteo Serenelli, Jose C Nicolau, Mark C Petrie, Chern-En Chiang, Sergey Tereshchenko, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Piotr Ponikowski, Marc S Sabatine, David L DeMets, Monika Dutkiewicz-Piasecka, Olof Bengtsson, Mikaela Sjöstrand, Anna Maria Langkilde, Pardeep S Jhund, John J V McMurray,

<h4>Background</h4>The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies reduced the risk of mortality and heart failure hospitalization and improved symptoms in patients with heart failure and reduced ejection fraction. We examined the effects of dapagliflozin according to age, given ... Read more >>

Circulation (Circulation)
[2020, 141(2):100-111]

Cited: 13 times

View full text PDF listing >>



Advertisement

Disclaimer
2.4383 s